Stasi, Alessandra
Fiorentino, Marco
Franzin, Rossana
Staffieri, Francesco
Carparelli, Sabrina
Losapio, Rosa
Crovace, Alberto
Lacitignola, Luca
Cimmarusti, Maria Teresa
Murgolo, Francesco
Stufano, Monica
Cafiero, Cesira
Castellano, Giuseppe
Sallustio, Fabio
Ferrari, Chiara
Ribezzi, Mario
Brienza, Nicola
Schirinzi, Annalisa
Di Serio, Francesca
Grasso, Salvatore
Pontrelli, Paola
Tupin, Cyrille
Barbaras, Ronald
Keyserling-Peyrottes, Constance
Crovace, Antonio
Gesualdo, Loreto
Funding for this research was provided by:
Abionyx Pharma
Article History
Received: 6 April 2023
Accepted: 29 August 2023
First Online: 2 November 2023
Declarations
:
: The animal study was reviewed and approved by the Ethical Committee of the Italian Ministry of Education, University and Research (MIUR) (Prot. n.1234/2020-PR). The pilot clinical study was approved by the Agenzia Italiana del Farmaco (AIFA) and by the Local Ethic Committee (N° EUDRACT 2020–004202-60, Protocol CER-001-SEP_AKI_01).
: All authors are agreed to the publication of this manuscript.
: LG received research funding from Abionyx and Sanofi (Granted to his University Department), and received speaker and consultancy fees from Fresenius, Estor, Werfen, Astellas, AstraZeneca, Travere, Sandoz, Baxter, Mundipharma, Pharmadoc, Retrophin, GSK, Novartis, and Chinook. CKP, RB, and CT are employees of Abionyx Pharma. MF received speaker fees from Estor. The remaining authors declare that they have no competing interests.